Our objective is to develop an assay based on magnetic particles (MPs) to determine the concentration of procalcitonin (PCT) using a chemiluminescence immunoassay (CLIA). Fluorescein isothiocyanate (FITC) and N-(aminobutyl)-N-(ethylisoluminol) (ABEI) were used to label two different anti-procalcitonin (PCT) monoclonal antibodies. The labeled antibodies, the PCT antigen, and the anti-FITC antibody-coated MPs formed a double-sandwiched immunocomplex. The measured relative light units (RLUs) of ABEI in the substrate solution were directly proportional to the amount of PCT present in the samples. The proposed method was linear to 600 ng/mL with a detection limit of 0.03 ng/mL. The coefficient of variation (CV) was <5% and <6% for the intra-and inter-assay precision, respectively. The average recoveries were between 95 and 107%. The linearity-dilution effect gave a linear correlation coefficient of 0.9912. This proposed assay provided an alternative method to quantitatively measure PCT in serum for the diagnosis of sepsis.
Introduction
Procalcitonin (PCT) is the precursor of the hormone calcitonin, and is 116 amino acids long with a molecular weight of 13 kDa. 1 Over the last several years, PCT has been identified as a biomarker that is strongly associated with cases of microbial infection. 2, 3 Systemic inflammatory response syndrome (SIRS) is systemic inflammation related to organ dysfunction and organ failure. 4, 5 Sepsis is a potentially deadly medical condition that is characterized by SIRS with a known infection or bacterial invasion into physiologically sterile tissue or body fluids. 6, 7 PCT levels are generally extremely low in healthy individuals, less 0.5 ng/mL, but in patients with sepsis, the PCT serum level increases within 4 h. The peak level of PCT is reached after 6 h and the concentration significantly increases up to 1000 ng/mL which is 2000-times the normal level. 4, 8 The PCT level will decrease within the normal range if the infection disappears. There are several biomarkers that are routinely used to detect sepsis, including the white blood cell (WBC) count, 9-11 the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) concentration. [12] [13] [14] However, it has become evident that these biomarkers are not as specific and sensitive as PCT. 12, 15 PCT has been formally approved by the FDA for use in hospital settings as a reliable marker to diagnose bacterial infections and disease severity as an indicator of sepsis. Serum PCT levels can be measured semiquantitatively using immunochromatography (BRAHMS PCT-Q, Henningsdorf, Germany). 16, 17 However, the imprecision and insensitivity of this analytic method have limited its widespread application. 18 There are two common quantitative assays for PCT in the clinical lab. The first is the LIAISON-BRAHMS PCT immunoluminometric assay (DiaSorin, Saluggia, Italy), which uses a monoclonal antibody immobilized on the surface of a coated tube and another monoclonal antibody labeled with a luminescent acridine tracer. The second is the VIDAS BRAHMS PCT assay, which is based on the enzyme-linked fluorescent immunoassay (bioMérieux, Durham, NC), and uses alkaline phosphatase to catalyze the substrate into a fluorescent product. The former method is a solid-phase immune reaction that has a low efficiency of antigen-antibody binding; the second one uses enzyme cataluminescence which is susceptible to the effect of the reaction temperature.
Chemiluminescence immunoassay (CLIA) has been widely used for clinical diagnoses because they emit no radioactive waste products, cause no enzyme precipitation and exhibit an acceptable sensitivity and a wide dynamic range. [19] [20] [21] Here, we report on a new CLIA for PCT that uses N-(aminobutyl)-N-(ethylisoluminol) (ABEI) as the luminescence substrate and magnetic particles that serve as both the solid phase and the separator in a liquid phase, offering many more active binding sites than a tube wall. Two different monoclonal antibodies are labeled with either ABEI or fluorescent-5-isothiocyanate (FITC). The PCT from serum combines first with the FITClabeled monoclonal antibody, and then with the magnetic particles (MPs) coated with the anti-FITC antibody. In a magnetic field, the unwanted materials are removed from PCT. The anti-ABEI antibody is then added to bind to PCT. Upon the addition of NaOH and H2O2, ABEI emits photons and forms a chemiluminescence (CL) signal. The concentration of PCT is directly related to the intensity of the CL.
In this study, the experimental conditions, including the dilution ratio of the ABEI-labeled anti-PCT antibody and FITC-labeled anti-PCT antibody, the volume of the MPs and the substrate were examined and optimized. Methodology parameters with respect to precision, detection limit and accuracy, for example, were evaluated. Our results demonstrate that this method is credible, and provides a new assay to determine PCT serum levels.
Experimental

Reagents and solutions
The PCT stock solution was purchased from Randox Life Sciences Co. (Antrim, UK). Two different monoclonal mouse anti-human PCT antibodies (ab90489 and ab166963) were The alpha-CGRP, beta-CGRP and calcitonin proteins were purchased from US Biological Co. (Swampscott, MA).
Highly purified distilled and deionized water was used throughout the study. Solutions of 20% bovine serum and 0.1 mol/L Tris-HCl buffer (pH 7.6) containing 0.5% BSA were used as dilution buffers for the ABEI-labeled anti-PCT antibody and the FITC-labeled anti-PCT antibody, respectively. A carbonate buffer solution (pH 9.0) and phosphate-buffered saline (PBS, pH 7.4) were used to label the anti-PCT antibodies with FITC and ABEI. A 0.05 mol/L Tris solution containing 0.05% Tween-20 (PBST) was used as the washing buffer.
Instrumentation
A commercially available instrument, the Maglumi 2000 Plus automatic analyzer (New Industries Biomedical Engineering Co., Ltd., Shenzhen, China), was used for the immunoassay procedures. The incubation and shaking procedures were performed in a temperature-regulated container (FYL-YS, China) and shaker (ZXWL-100, China). A Model XW-80A vortex mixer (Jingke Industrial, Shanghai, China) was used for thorough mixing of substances.
The FITC-labeled anti-PCT antibody
The FITC-labeled anti-PCT antibody was prepared according to published methods, [22] [23] [24] but with slight modifications. A 10-mL solution of anti-PCT was adjusted to 12 mg/mL using 0.5 mol/L (pH 9.0) Na2CO3 buffer and normal saline. One point three milligrams of FITC was gradually added to the anti-PCT solution over a course of approximately 5 -10 min, and the solution was stirred for 12 h at 4 C in the dark. Then, the labeled anti-PCT solution was centrifuged (2500 r/min) for 20 min to remove a small amount of sediment, put into a dialysis bag, and then placed in a beaker of pH 9.0 saline buffer (0 -4 C) overnight. The protein concentration of the conjugate was measured according to the absorbance at 280 and 495 nm. The FITC-labeled anti-PCT antibody conjugate was stored at -20 C until further use.
The ABEI-labeled anti-PCT antibody
The anti-PCT antibody labeled with ABEI was prepared as previously described. 25, 26 Briefly, the PCT antibody was diluted to 3.2 mg/mL using 0.1 mol/L PBS (pH 7.4). Five hundred microliters containing 165 mg/ml ABEI, 35 mg/mL NHS, and 15 mg/mL EDC was added to 500 μL of the 3.2 mg/mL anti-PCT solution and incubated for 1 h at 37 C. The unreacted reagents were removed via dialysis for 2 days with 0.1 mol/L PBS (pH 7.4). The protein concentration of the conjugate was measured according to the absorbance at 280 and 495 nm. The ABEI-labeled anti-PCT antibody conjugate was stored at -20 C until further use.
Calibrator preparation
For calibration purposes, the PCT stock solution was diluted in a BSA/PBS solution (0.008 mol/L Na2HPO4, 0.003 mol/L KH2PO4, 0.15 mol/L NaCl, 10 g/L BSA, 0.2% NaN3, pH 7.4) to reach the target concentrations of 0.00, 2.00, 10.00, 50.00, 300.00 and 600.00 ng/mL, which were named S0, S1, S2, S3, S4 and S5, respectively. Calibrators were divided into aliquots (500 μL), and stored at -20 C until further use.
Immunoassay procedure
For the immunoassay, 40 μL of the PCT calibrator solution or serum samples, 100 μL of the FITC-labeled anti-PCT antibody and 200 μL of ABEI-labeled anti-PCT antibody were added into the tube and incubated for 10 min at 37 C. Then, 20 μL of MPs coated with the goat anti-mouse FITC polyclonal antibody were added into the tube. After a 10 min incubation period at 37 C, unwanted materials were removed from the tubes by washing once with 400 μL of a washing solution in a magnetic field. Finally, 100 μL of the CL substrate solution (50 μL NaOH and 50 μL H2O2) was added, and the relative light units (RLUs) were measured in the dark. A schematic illustration of the CLIA principle is shown in Fig. 1 .
Data analysis
Calibrator and experimental samples were measured in duplicate wells, and the CL intensity values were averaged. A linear-fit standard curve was obtained by plotting the logarithm of the RLU (log Y ) against the logarithm of the analyte concentration (log X ). Data were analyzed with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA).
Results
Optimization of immunoassay reagents
As shown in Table 1 , when the FITC-labeled anti-PCT antibody stock solution (1.85 mg/mL) was serially diluted from 1:200 to 1:1000, the corresponding RLUs decreased gradually. The linear range and sensitivity of an immunoreaction is influenced by the dilution ratio of the reagents; thus, we built a calibration curve to optimize the immunoassay reagents. The 1:400 dilution showed high sensitivity (the highest RLUS1/ RLUS0) and a wide linear range (the highest RLUS5/RLUS0). Similarly, the ABEI-labeled anti-PCT antibody stock solution (0.36 mg/mL) was serially diluted from 1:100 to 1:500, and the corresponding RLUs decreased gradually. According to the RLUS1/RLUS0 and RLUS5/RLUS0 values, the 1:200 dilution of ABEI-labeled anti-PCT was selected for the remaining analyses ( Table 2 ).
The influence of the volume of the magnetic particles
The quantity of magnetic beads was critical for the analytical system. Volumes of the MPs (5.0 mg/mL) were optimized between 10 and 60 μL. As shown in Fig. 2 , the RLUs increased as the volume of MPs increased between 10 and 20 μL, but as the volume of MPs was increased from 20 to 60 μL, the RLUs reached a plateau or decreased. Thus, a 20 μL volume of MPs was chosen for further experimentation.
Influence of the volume of the substrate
The CL substrate volume was directly proportional to the CL intensity and assay sensitivity. In this experiment, the volume The ABEI-anti PCT antibody at a 1:200 ratio, 20 μL of the anti-FITC coated MPs and 100 μL of the CL substrate were incubated at 37 C for 10 min. S0, S1, S5 were 0.00, 2.00, 600 ng/mL calibrator, respectively. The FITC-anti PCT antibody at a 1:400 dilution, 20 μL of anti-FITC coated MPs and 100 μL of the CL substrate were incubated at 37 C for 10 min. S0, S1, S5 were 0.00, 2.00, 600 ng/mL calibrator, respectively.
of the substrate was investigated from 50 to 200 μL. As shown in Fig. 2 , the RLUs did not change with increasing CL substrate volumes up to 100 μL, and then decreased slowly with additional substrate. Therefore, we set the optimal substrate volume at 100 μL.
Evaluation of the methodology Detection limit.
Under the optimal conditions, a standard curve of log Y = 0.6437log X + 4.1247 was obtained with a correlation coefficient of 0.9747. The average RLU and standard deviation (SD) of the 10 replicates of S0 were 985 and 205. The sum of the average RLU and 2SD was considered as a single of the detection limit. According to the standard curve, the concentration of the detection limit was 0.03 ng/mL. Precision. Three different concentrations of serum samples were measured 10 times within one assay to evaluate the intra-assay precision. The same samples were analyzed 5 times over a period of 4 days to measure the inter-assay precision. As shown in Table 3 , the coefficient of variation (CV) was <5% and <6% for intra-and inter-assay precision, respectively. Recovery. The recovery test is a useful approach to check the accuracy of a method. Different amounts of PCT (0.50, 2.00 and 30.00 ng/mL) were added to three human sera samples to obtain different distributions; the samples were measured five times. The average recoveries (Table 4) were between 95.4 and 106.9%, indicating that the results of the proposed method are satisfactory. Linearity-dilution effect. A linearity-dilution test was performed to evaluate whether the highly concentrated samples could be accurately quantified after dilution. In this experiment, a serum sample from a patient (approximately 600 ng/mL) was diluted by S0 to obtain a series of concentrations, which were 1:2, 1:4, 1:8, 1:16 and 1:32 of the original concentration. Each sample was measured in duplicate. The relationship between the concentration of the diluted PCT and the dilution ratios had a favorable linear correlation coefficient of 0.9912 (Fig. 3) . Selectivity. The selectivity of the proposed method was evaluated by using calcitonin, alpha-CGRP and beta-CGRP, whose test concentrations were significantly higher than the normal human serum concentrations. The cross-reactivity (CR) was calculated as follows: CR = C(PCT)/C(cross-reactant) × 100%, where C(PCT) refers to the PCT concentration determined by applying the tested cross-reactant signal to the dose-response curve, and C(cross-reactant) refers to the cross-reactant concentration. The results showed that the CR of the PCT antibodies to crossreact with calcitonin (15 ng/mL), alpha-CGRP (8500 ng/mL) and beta-CGRP (8500 ng/mL) were 0.13, 0.03 and 0.06%, respectively (Table 5) . Therefore, the anti-PCT monoclonal 
Discussion
PCT is a known sensitive and specific biomarker of bacterial and viral infections, and is regarded as being the most helpful laboratory marker to differentiate between sepsis and SIRS. [27] [28] [29] A routine rapid laboratory test for PCT has been a subject of interest in a number of studies. The objective of the present work was to develop a rapid and high-performance method to test PCT levels in human serum. The proposed assay comprised an immunological "sandwich" reaction where a FITC-labeled anti-PCT antibody, serum PCT and MPs coated with an anti-FITC antibody combine. Unwanted material was washed away, and then the added ABEI-labeled anti-PCT antibody forms a MPs-immune complex. Upon adding the CL substrate, ABEI emited light, and the RLU was proportional to the level of PCT in the serum sample. An entire test can be finished in 25 min. In the present method, the anti-PCT monoclonal antibody did not directly combine with the magnetic beads, but with FITC, which played the role of a bridge in the reaction. This design could guarantee a complete liquid-phase, and shorten the reaction time.
In the immunological "sandwich" reaction, an appropriate excess of immunoreaction reagents is important for the assay sensitivity and linear range. Therefore, the stock concentrations of the ABEI-labeled anti-PCT antibody and the FITC-labeled anti-PCT antibody were optimized. Three calibrators (S0, S1 and S5) were tested to determine the optimal dilution ratios of the ABEI-labeled anti-PCT antibody and the FITC-labeled anti-PCT antibody. As displayed in Table 1 , the dilution ratio of 1:400 was selected as being the optimal one for the FITC-labeled anti-PCT antibody, because it corresponded to the widest linear range (the highest RLUS5/RLUS0) and the highest sensitivity (the highest RLUS1/RLUS0). In Table 2 , the dilution ratio of 1:100 for ABEI-labeled anti-PCT shows the best sensitivity and dilution ratio of 1:200 exhibited the widest linear range. Considering the performance and reagent cost, the dilution ratio of 1:200 was selected for further research.
In this experiment, MPs were used as the separation agent. Compared to the antibodies immobilized on the surface of coated tubes, our method offers many more active binding sites for the immobilized proteins, promising an improved analytical performance. 30 However, too many MPs could absorb the emitted light and decrease the sensitivity. As shown in Fig. 3 , the RLUs exhibited a decreasing trend when the volume of the MPs was over 20 μL. Hence, we set the volume of MPs at 20 μL.
The methodology parameters, such as selectivity and linear range, have been evaluated carefully. PCT is the precursor of the hormone calcitonin. Two isoforms of calcitonin gene-related peptide (CGRP), alpha-CGRP and beta-CGRP, are widely expressed in serum. 31, 32 To study the selectivity of this assay, we tested the cross-reactivity of PCT to both isoforms of calcitonin; and our assay exhibited a little cross-reactivity, which was acceptable for the analysis.
The intra-and inter-assay coefficients of variation of the present method were below 5 and 6%, respectively. The accuracy of our method was examined, and exhibited recoveries ranging between 95.4 and 106.9%.
The results of the linearity-dilution effect suggested that the proposed method can provided accurate quantification for samples beyond the detectable limit. Compared with the existing commercial kits, this method required less time for an entire test, and had a wider linear range.
In the present study, we used ABEI to label a PCT antibody, and established a new chemiluminescence immunoassay method that has the potential to promote the general application of PCT in the basic level hospitals and small scale laboratories.
